RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma

Area of Science:

• Oncology
• Genetics
• Bioinformatics

Background:

• Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive lymphoma with high relapse rates.
• RAB39B, a Ras-oncogene superfamily member, is implicated in various tumors, but its role in DLBCL remains unclear.

Purpose of the Study:

• To investigate the role of RAB39B in DLBCL using integrated bioinformatics analysis.
• To identify potential diagnostic and therapeutic biomarkers for DLBCL.

Main Methods:

• Utilized TIMER, UCSC, GEO, and TCGA databases for expression and correlation analyses.
• Employed LinkedOmics, STRING, starBase, and miRNet2.0 for pathway, network, and ceRNA construction.
• Analyzed immune cell infiltration, m6A modification, and drug sensitivity via GSCA database.

Main Results:

• RAB39B was highly expressed in DLBCL and associated with DNA replication, protein synthesis, and key signaling pathways (JAK-STAT, NF-kappa B).
• RAB39B expression negatively correlated with immune cell infiltration and was linked to 14 m6A modifier genes.
• Elevated RAB39B predicted decreased sensitivity to chemotherapy drugs and poor overall survival (OS) in DLBCL patients.

Conclusions:

• Abnormal RAB39B elevation in DLBCL is linked to drug resistance and poor prognosis.
• RAB39B's involvement in immune infiltration, m6A modification, and non-coding RNA regulation contributes to its role in DLBCL.
• RAB39B shows potential as a biomarker for DLBCL diagnosis and treatment.